Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. MDGL | 0.00 |
Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:
MDGL) with a Buy and raises the price target from $578 to $587.